Innovus Pharmaceuticals Inc (INNV) 0.4750 $INNV
Post# of 273249
Posted On: 08/21/2016 7:07:56 AM
Innovus Pharmaceuticals Inc (INNV) 0.4750 $INNV
SECFilings.com: Innovus Pharma (INNV) Reaches a Positive Cash Flow & Issues Strong Outlook
Marketwired - Thu Aug 18, 5:00AM CDT
Independent Analyst Suggests Price Target 170% Higher Than Current Levels Based on Strong Future Growth and Profitability
SeeThruEquity Issues Update on Innovus Pharmaceuticals, Inc. (OTCQB: INNV) and Raises Price Target to $1.00
ACCESSWIRE - Mon Aug 15, 5:00AM CDT
NEW YORK, NY / ACCESSWIRE / August 15, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Innovus Pharmaceuticals, Inc. (OTCQB: INNV).
SECFilings.com: Innovus Pharma (INNV) Quarterly Revenue Soars Past $1M on 446% Growth With Positive Cash Flow
Marketwired - Thu Aug 11, 5:00AM CDT
REDONDO BEACH, CA--(Marketwired - Aug 11, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the release of an article covering Innovus Pharmaceuticals' (OTCQB: INNV) recent quarterly financial results and the numerous upcoming catalysts for the company's stock.
Innovus Pharma Turns Cash Flow Positive With Over $1 Million in Revenues for the Second Quarter 2016
Marketwire Canada - Tue Aug 09, 2:47PM CDT
Company Affirms Its Previously Announced Revenue Guidance of $5 Million for 2016
Innovus Pharmaceuticals to Host Its Second Quarter 2016 Financial Report Conference Call on August 9, 2016 at 4:15 p.m. EDT
Marketwire Canada - Fri Aug 05, 1:00PM CDT
SAN DIEGO, CA--(Marketwired - Aug 5, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
www.innovuspharma.com (OTCQB: INNV) announced today it will release its second quarter 2016 financial results before the open of trading on Tuesday, August 9, 2016 ahead of its 10-Q to be filed on August 15, 2016. The company will host a conference call at 4:15 p.m. EDT/1:15 p.m. PDT on the same day (August 9, 2016) to discuss the financial results and recent business developments.
Innovus Pharma Resumes Commercial Sale of Zestra With the Appointment of PT Laras Bumi Resources as Its Distributor for Select Asian Countries Including Japan, Korea, Indonesia and China
Marketwired - Thu Aug 04, 5:00AM CDT
PT Laras Bumi Resources Projects Close to 150,000 Units a Year
Innovus Pharmaceuticals Announces the Closing of Its $3M Private Financing From Institutional Investors
Marketwired - Mon Aug 01, 5:00AM CDT
Company in a Strong Cash Position for Product Launches and Expedited Growth
SECFilings.com Examines Innovus Pharmaceuticals' (INNV) Position in Multi-Billion Dollar Female Sexual Dysfunction Market
Marketwire Canada - Tue Jun 21, 8:01AM CDT
REDONDO BEACH, CA--(Marketwired - Jun 21, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, takes a look at the underserved Female Sexual Interest Arousal Dysfunction (FSI/AD) market and Innovus Pharmaceuticals' (OTCQB: INNV) clinically proven over-the-counter treatment, Zestra®.
Innovus Pharmaceuticals Announces Successful Top Line Results From RecalMax in Memory, Processing Speed and Thought Maintenance
Marketwired - Mon Jun 13, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 13, 2016) - Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases, announced today that the Company's top line results from its RecalMax™ U.S. four month human survey use clinical trial in people with low memory and learning.
Innovus Pharma (INNV)'s Vesele Could Be the Best Complementary Product for Viagra and Cialis's $3.2 Billion Dollar Erectile Dysfunction Market
Marketwire Canada - Thu Jun 09, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 9, 2016) - Innovus Pharma (OTCQB: INNV) -- The global erectile dysfunction drug market is expected to reach $3.2 billion USD by 2022 according to a new report by Grand View Research Inc. Male sexual dysfunction has become a multi-billion-dollar market fueled by sales of erectile dysfunction drugs like Viagra and Cialis. In fact, Pfizer Inc.'s Viagra surpassed $1 billion in sales during its first year despite having lower than usual third-party coverage. The drug has consistently surpassed $1 billion per year in sales since its launch and even briefly reached above the $2 billion mark back in 2012 despite growing competition.
PFE: 34.98 (-0.21)
Innovus Pharma Announces the Filing of the Product Licenses for Zestra, Zestra Glide, EjectDelay and Sensum+ With the Indian FDA (Directorate General of Health Services) by Its Partner Khandelwal Laboratories
Marketwire Canada - Tue Jun 07, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 7, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma" (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that its partner Khandelwal Laboratories filed the product licenses for Zestra®, Zestra Glide®, EjectDelay® and Sensum+® with the Indian FDA, The Drugs Controller General (India) and the Directorate General of Health Services to commercialize the products in India.
SECFilings.com: Innovus Pharma (INNV) Reaches a Positive Cash Flow & Issues Strong Outlook
Marketwired - Thu Aug 18, 5:00AM CDT
Independent Analyst Suggests Price Target 170% Higher Than Current Levels Based on Strong Future Growth and Profitability
SeeThruEquity Issues Update on Innovus Pharmaceuticals, Inc. (OTCQB: INNV) and Raises Price Target to $1.00
ACCESSWIRE - Mon Aug 15, 5:00AM CDT
NEW YORK, NY / ACCESSWIRE / August 15, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Innovus Pharmaceuticals, Inc. (OTCQB: INNV).
SECFilings.com: Innovus Pharma (INNV) Quarterly Revenue Soars Past $1M on 446% Growth With Positive Cash Flow
Marketwired - Thu Aug 11, 5:00AM CDT
REDONDO BEACH, CA--(Marketwired - Aug 11, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the release of an article covering Innovus Pharmaceuticals' (OTCQB: INNV) recent quarterly financial results and the numerous upcoming catalysts for the company's stock.
Innovus Pharma Turns Cash Flow Positive With Over $1 Million in Revenues for the Second Quarter 2016
Marketwire Canada - Tue Aug 09, 2:47PM CDT
Company Affirms Its Previously Announced Revenue Guidance of $5 Million for 2016
Innovus Pharmaceuticals to Host Its Second Quarter 2016 Financial Report Conference Call on August 9, 2016 at 4:15 p.m. EDT
Marketwire Canada - Fri Aug 05, 1:00PM CDT
SAN DIEGO, CA--(Marketwired - Aug 5, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
www.innovuspharma.com (OTCQB: INNV) announced today it will release its second quarter 2016 financial results before the open of trading on Tuesday, August 9, 2016 ahead of its 10-Q to be filed on August 15, 2016. The company will host a conference call at 4:15 p.m. EDT/1:15 p.m. PDT on the same day (August 9, 2016) to discuss the financial results and recent business developments. Innovus Pharma Resumes Commercial Sale of Zestra With the Appointment of PT Laras Bumi Resources as Its Distributor for Select Asian Countries Including Japan, Korea, Indonesia and China
Marketwired - Thu Aug 04, 5:00AM CDT
PT Laras Bumi Resources Projects Close to 150,000 Units a Year
Innovus Pharmaceuticals Announces the Closing of Its $3M Private Financing From Institutional Investors
Marketwired - Mon Aug 01, 5:00AM CDT
Company in a Strong Cash Position for Product Launches and Expedited Growth
SECFilings.com Examines Innovus Pharmaceuticals' (INNV) Position in Multi-Billion Dollar Female Sexual Dysfunction Market
Marketwire Canada - Tue Jun 21, 8:01AM CDT
REDONDO BEACH, CA--(Marketwired - Jun 21, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, takes a look at the underserved Female Sexual Interest Arousal Dysfunction (FSI/AD) market and Innovus Pharmaceuticals' (OTCQB: INNV) clinically proven over-the-counter treatment, Zestra®.
Innovus Pharmaceuticals Announces Successful Top Line Results From RecalMax in Memory, Processing Speed and Thought Maintenance
Marketwired - Mon Jun 13, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 13, 2016) - Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counter ("OTC"
and consumer products for men's and women's health, vitality and respiratory diseases, announced today that the Company's top line results from its RecalMax™ U.S. four month human survey use clinical trial in people with low memory and learning. Innovus Pharma (INNV)'s Vesele Could Be the Best Complementary Product for Viagra and Cialis's $3.2 Billion Dollar Erectile Dysfunction Market
Marketwire Canada - Thu Jun 09, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 9, 2016) - Innovus Pharma (OTCQB: INNV) -- The global erectile dysfunction drug market is expected to reach $3.2 billion USD by 2022 according to a new report by Grand View Research Inc. Male sexual dysfunction has become a multi-billion-dollar market fueled by sales of erectile dysfunction drugs like Viagra and Cialis. In fact, Pfizer Inc.'s Viagra surpassed $1 billion in sales during its first year despite having lower than usual third-party coverage. The drug has consistently surpassed $1 billion per year in sales since its launch and even briefly reached above the $2 billion mark back in 2012 despite growing competition.
PFE: 34.98 (-0.21)
Innovus Pharma Announces the Filing of the Product Licenses for Zestra, Zestra Glide, EjectDelay and Sensum+ With the Indian FDA (Directorate General of Health Services) by Its Partner Khandelwal Laboratories
Marketwire Canada - Tue Jun 07, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 7, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
(OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that its partner Khandelwal Laboratories filed the product licenses for Zestra®, Zestra Glide®, EjectDelay® and Sensum+® with the Indian FDA, The Drugs Controller General (India) and the Directorate General of Health Services to commercialize the products in India. 
(0)
(0)Scroll down for more posts ▼